BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bolin K, Niska PÅ, Pirhonen L, Wasling P, Landtblom AM. The cost utility of pitolisant as narcolepsy treatment. Acta Neurol Scand 2020;141:301-10. [PMID: 31838740 DOI: 10.1111/ane.13202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Gauffin H, Fast T, Komkova A, Berntsson S, Boström I, Landtblom AM. Narcolepsy treatment in Sweden: An observational study. Acta Neurol Scand 2022;145:185-92. [PMID: 34611886 DOI: 10.1111/ane.13532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 El-Solh AA, Rudraraju A, Pasrija D, Bui H. Pharmacotherapy of residual excessive sleepiness among continuous positive airway pressure (CPAP) treated patients with sleep apnea. Expert Opin Pharmacother 2022;:1-10. [PMID: 35045769 DOI: 10.1080/14656566.2022.2029408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sieminski M, Skrzypek-Czerko M, Chełminiak Ł. Therapy satisfaction and willingness-to-pay in Polish patients with restless legs syndrome. Sleep Breath 2021. [PMID: 34333733 DOI: 10.1007/s11325-021-02440-x] [Reference Citation Analysis]
4 Guevarra JT, Hiensch R, Varga AW, Rapoport DM. Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility. Nat Sci Sleep 2020;12:709-19. [PMID: 33117007 DOI: 10.2147/NSS.S264140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]